---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093723"
form_type: "8-K"
ticker: "VREOF"
cik: "0001771706"
company_name: "Vireo Growth Inc."
filed_at: "2026-08-11T11:11:16+00:00"
generated_at: "2026-08-11T11:15:23.138554+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vireo Q2 GAAP revenue $209.3M up 335% YoY; proforma $254.9M; ~270 dispensaries

## Summary
- Q2 GAAP revenue $209.3M (+335% YoY); gross profit $95.3M (45.5% margin); adjusted EBITDA $41.5M (19.8% margin).
- Proforma revenue $254.9M reflects Hawthorne, Bridgewell, PharmaCann deals; closed Hawthorne, Eaze, Bridgewell in Q2.
- Post-Q2: closed PharmaCann; announced FLUENT, C21, Planet 13 merger, Cannabist asset purchase, and Ohio vertical.
- New ABL facility: $65M initial, expandable to $105M at SOFR+1.75%-2.00%; Q2 cash $122.7M.
- Company expects to become largest U.S. cannabis operator by dispensary count with approximately 270 stores.

## SEC filing metadata
- accession: 0001104659-26-093723
- form_type: 8-K
- ticker: VREOF
- cik: 0001771706
- company_name: Vireo Growth Inc.
- filed_at: 2026-08-11T11:11:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771706/000110465926093723/0001104659-26-093723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771706/000110465926093723/vreof-20260811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093723
- JSON: https://secwatch.observer/filing/0001104659-26-093723.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.